DexCom Inc. Stock Outperforms Competitors On Strong Trading Day

Prospect Capital Corp

Change company Symbol lookup

Select an option...

PSEC Prospect Capital Corp

SPEC Spectralcast Inc

RC Ready Capital Corp

GNK Genco Shipping & Trading Ltd

NVOS Novo Integrated Sciences Inc

PDRDF Pernod Ricard SA

RKDA Arcadia Biosciences Inc

BBVA Banco Bilbao Vizcaya Argentaria SA

GIC Global Industrial Co

EQHA EQ Health Acquisition Corp

Financials : Capital Markets | Small Cap Blend

Company profile

Prospect Capital Corporation is a financial services company that primarily lends to and invests in middle-market privately held companies. The Company's investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. It invests primarily in senior and subordinated secured debt and equity of private companies in need of capital for acquisitions, divestitures, growth, development, recapitalizations and other purposes. It makes directly originated agented loans to companies, including companies which are controlled by private equity sponsors and companies that are not controlled by private equity sponsors. It also invests in senior and secured loans, syndicated loans and high yield bonds that have been sold to a club or syndicate of buyers, both in the primary and secondary markets. The Company is managed by its investment adviser, Prospect Capital Management L.P.

DexCom Inc. Stock Outperforms Competitors On Strong Trading Day

4:51 pm ET January 11, 2022 (MarketWatch) Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of DexCom Inc. (DXCM) advanced 4.07% to $481.17 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index rising 0.92% to 4,713.07 and the Dow Jones Industrial Average rising 0.51% to 36,252.02. The stock's rise snapped a seven-day losing streak. DexCom Inc. closed $178.28 below its 52-week high ($659.45), which the company reached on November 18th.

The stock outperformed some of its competitors Tuesday, as Johnson & Johnson (JNJ) fell 1.06% to $171.25, Abbott Laboratories (ABT) rose 0.33% to $135.70, and Medtronic PLC (MDT) rose 2.15% to $107.89. Trading volume (1.2 M) eclipsed its 50-day average volume of 760,971.

Data source: Dow Jones Market Data, FactSet. Data compiled Janurary 11, 2022.

-MarketWatch Automation

(END) Dow Jones Newswires

January 11, 2022 16:51 ET (21:51 GMT)